01:10 , May 13, 2017 |  BioCentury  |  Emerging Company Profile

Dialing down dynamin

Dynacure S.A.S. is developing an antisense oligonucleotide against DNM2 that could treat all three subtypes of centronuclear myopathy, two of which are not covered by industry’s pipeline. Centronuclear myopathy (CNM) is a group of rare...
07:00 , Oct 13, 2014 |  BioCentury  |  Emerging Company Profile

Audentes: Muscular gene therapies

Audentes Therapeutics Inc. is developing gene therapies to treat rare musculoskeletal diseases, including one with no approved therapy and another where a gene therapy could provide increased efficacy, safety and convenience over a marketed enzyme...
08:00 , Nov 8, 2012 |  BC Innovations  |  Cover Story

Turning lupus against cancer

Yale School of Medicine researchers have shown that a lupus autoantibody inhibited DNA repair mechanisms in cancer cells and sensitized mice to radiation and chemotherapy. 1 The group is planning Phase I trials of the...